Review article · 2026

Conditional biologics in cancer immunotherapy: mechanisms, applications and clinical progress

Bridget P. Keenan, Justin R Killebrew, Diane L. Hollenbaugh, Lawrence H. Fong

Nature Reviews Drug Discovery · Published 9 November 2026 · DOI 10.1038/s41573-026-01552-x

View at the publisherCite this paper

In brief

“Conditional biologics in cancer immunotherapy: mechanisms, applications and clinical progress” is a 2026 review article by Bridget P. Keenan and 3 co-authors, published in Nature Reviews Drug Discovery. OpenAlex counts 0 citations as of 18 November 2026. The publisher's version is not open access, and OpenAlex records no free legal copy.

Citations
0
References
204
Authors
4

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Keenan, B. P., Killebrew, J. R., Hollenbaugh, D. L., & Fong, L. H. (2026). Conditional biologics in cancer immunotherapy: mechanisms, applications and clinical progress. Nature Reviews Drug Discovery. https://doi.org/10.1038/s41573-026-01552-x

MLA 9

Keenan, Bridget P., et al. “Conditional biologics in cancer immunotherapy: mechanisms, applications and clinical progress.” Nature Reviews Drug Discovery, 2026. https://doi.org/10.1038/s41573-026-01552-x.

Chicago

Keenan, Bridget P., Justin R Killebrew, Diane L. Hollenbaugh, and Lawrence H. Fong. 2026. “Conditional biologics in cancer immunotherapy: mechanisms, applications and clinical progress.” Nature Reviews Drug Discovery. https://doi.org/10.1038/s41573-026-01552-x.

Harvard

Keenan, B. P. et al. (2026) ‘Conditional biologics in cancer immunotherapy: mechanisms, applications and clinical progress’, Nature Reviews Drug Discovery. doi:10.1038/s41573-026-01552-x.

IEEE

B. P. Keenan, J. R. Killebrew, D. L. Hollenbaugh, and L. H. Fong, “Conditional biologics in cancer immunotherapy: mechanisms, applications and clinical progress,” Nature Reviews Drug Discovery, 2026, doi: 10.1038/s41573-026-01552-x.

BibTeX

@article{keenan2026conditional,
  title     = {{Conditional biologics in cancer immunotherapy: mechanisms, applications and clinical progress}},
  author    = {Keenan, Bridget P. and Killebrew, Justin R and Hollenbaugh, Diane L. and Fong, Lawrence H.},
  journal   = {Nature Reviews Drug Discovery},
  year      = {2026},
  doi       = {10.1038/s41573-026-01552-x},
  url       = {https://doi.org/10.1038/s41573-026-01552-x}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers

  • cancer immunotherapy
  • tumor microenvironment
  • immune-related adverse events
  • cytokine release syndrome
  • tumor accumulation
  • immune checkpoint inhibitors
  • therapeutic window
  • clinical trials

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Keenan, B. P., Killebrew, J. R., Hollenbaugh, D. L., & Fong, L. H. (2026). Conditional biologics in cancer immunotherapy: mechanisms, applications and clinical progress. Nature Reviews Drug Discovery. https://doi.org/10.1038/s41573-026-01552-x

How many times has this paper been cited?

0 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.

Who wrote this paper?

Bridget P. Keenan, Justin R Killebrew, Diane L. Hollenbaugh, Lawrence H. Fong.

What is the DOI of this paper?

10.1038/s41573-026-01552-x, permanently at https://doi.org/10.1038/s41573-026-01552-x. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.